Transaction in Own Shares

Summary by AI BETAClose X

Hikma Pharmaceuticals PLC reports that between June 8 and June 12, 2026, it repurchased a total of 770,375 ordinary shares as part of its $250 million share repurchase program. The company intends to cancel these repurchased shares. Since the program's inception on February 26, 2026, Hikma has bought back 8,565,676 ordinary shares for a total cost of £114,704,012.53. Following the cancellation of the recently repurchased shares, the company will have 213,320,777 ordinary shares in issue.

Disclaimer*

UK 100

Latest directors dealings